Guiqing Liang

发表

Identification of saturated and unsaturated fatty acids released during microsomal incubations

U. Argikar, J. Bushee, Guiqing Liang, 2014, Xenobiotica; the fate of foreign compounds in biological systems.

The activities of drug inactive ingredients on biological targets

Samuel T. Slocum, E. Berg, J. Irwin, 2020, Science.

Discovery of N-[5-(6-Chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a Cortisol-Sparing CYP11B2 Inhibitor that Lowers Aldosterone in Human Subjects.

Lu Gan, J. Vest, G. Ksander, 2015, Journal of medicinal chemistry.

Structure-Guided Design of Substituted Biphenyl Butanoic Acid Derivatives as Neprilysin Inhibitors.

A. D'arcy, M. Mogi, C. Wiesmann, 2020, ACS medicinal chemistry letters.

The discovery of potent inhibitors of aldosterone synthase that exhibit selectivity over 11-beta-hydroxylase.

C. Springer, G. Ksander, D. Rigel, 2010, Bioorganic & medicinal chemistry letters.

Indole- and indolizine-glyoxylamides displaying cytotoxicity against multidrug resistant cancer cell lines.

Lijun Sun, D. A. James, W. Ying, 2008, Bioorganic & medicinal chemistry letters.

Syntheses and antitumor activities of N'1,N'3-dialkyl-N'1,N'3-di-(alkylcarbonothioyl) malonohydrazide: the discovery of elesclomol.

J. Wu, Lijun Sun, Shoujun Chen, 2013, Bioorganic & medicinal chemistry letters.

Compound Property Optimization in Drug Discovery Using Quantitative Surface Sampling Micro Liquid Chromatography with Tandem Mass Spectrometry.

K. Mansfield, S. Hintermann, Adam Bentley, 2016, Analytical chemistry.

Discovery of a Brain Penetrant ATP-competitive Inhibitor of the Mechanistic Target of Rapamycin (mTOR) for CNS disorders.

D. Curtis, F. Lombardo, Christopher J. Wilson, 2020, Journal of medicinal chemistry.

JPET # 167148-1-Pharmacodynamic and pharmacokinetic characterization of the aldosterone synthase inhibitor FAD 286 in two rodent models of hyperaldosteronism : comparison with the 11 β-hydroxylase inhibitor metyrapone

D. Rigel, Guiqing Liang, M. Beil, 2010 .

Structure-based design and pre-clinical characterization of selective and orally bioavailable Factor XIa inhibitors: Demonstrating the power of an integrated S1 protease family approach.

V. Hornak, E. Altmann, A. D'arcy, 2020, Journal of medicinal chemistry.

Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Orally Bioavailable and Brain Penetrant Mutant IDH1 Inhibitors.

B. Firestone, Abran Q. Costales, C. Shafer, 2018, ACS medicinal chemistry letters.

Evaluation of pharmaceutical excipients as cosolvents in 4-methyl umbelliferone glucuronidation in human liver microsomes: applications for compounds with low solubility.

U. Argikar, V. Hosagrahara, Wendy Lee, 2011, Drug Metabolism and Pharmacokinetics.

Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor.

B. Firestone, Abran Q. Costales, C. Shafer, 2017, ACS medicinal chemistry letters.

Defective Autophagy and mTORC1 Signaling in Myotubularin Null Mice

Jeffrey A. Porter, P. Finan, K. Walsh, 2012, Molecular and Cellular Biology.

1 Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research,

Jeffrey A. Porter, P. Finan, K. Walsh, 2012 .

Signaling in Myotubularin Null Mice Defective Autophagy and mTORC 1

Jeffrey A. Porter, P. Finan, K. Walsh, 2012 .

Structure-Activity Relationships, Pharmacokinetics, and in Vivo Activity of CYP11B2 and CYP11B1 Inhibitors.

Adam Amaral, G. Ksander, D. Rigel, 2015, Journal of medicinal chemistry.

Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects

J. Ménard, S. Rebello, D. Rigel, 2014, Journal of Translational Medicine.

Pharmacodynamic and Pharmacokinetic Characterization of the Aldosterone Synthase Inhibitor FAD286 in Two Rodent Models of Hyperaldosteronism: Comparison with the 11β-Hydroxylase Inhibitor Metyrapone

D. Rigel, A. Jeng, F. Fu, 2010, Journal of Pharmacology and Experimental Therapeutics.

Discovery of a Novel Piperidine-Based Inhibitor of Cholesteryl Ester Transfer Protein (CETP) That Retains Activity in Hypertriglyceridemic Plasma.

O. Ohmori, Kayo Yasoshima, Ken Yamada, 2017, Journal of medicinal chemistry.

Discovery of 2-Pyridylpyrimidines as the First Orally Bioavailable GPR39 Agonists.

A. Bose, S. Peukert, R. Jain, 2014, ACS medicinal chemistry letters.

Pharmacokinetics, excretion, and distribution of combretastatin A4 phosphate in rats.

Li Wang, Shi-long Zhong, Wen-Sheng Huang, 2012, Die Pharmazie.

Systematic Evaluation of Wajima Superposition (Steady-State Concentration to Mean Residence Time) in the Estimation of Human Intravenous Pharmacokinetic Profile.

F. Lombardo, Giuliano Berellini, Guiqing Liang, 2016, Journal of pharmaceutical sciences.

Pharmacokinetics , Pharmacodynamics and Drug Transport and Metabolism Systematic Evaluation of Wajima Superposition ( Steady-State Concentration to Mean Residence Time ) in the Estimation of Human Intravenous Pharmacokinetic Pro fi le

F. Lombardo, Giuliano Berellini, Guiqing Liang, 2022 .

Seizure reduction in TSC2-mutant mouse model by an mTOR catalytic inhibitor.

D. Curtis, Christopher J. Wilson, A. Rotenberg, 2023, Annals of clinical and translational neurology.

Identification of Brain-Penetrant ATP-Competitive mTOR Inhibitors for CNS Syndromes.

D. Curtis, Christopher J. Wilson, P. Furet, 2023, Journal of Medicinal Chemistry.

Pharmacodynamic and Pharmacokinetic Characterization of the Aldosterone Synthase Inhibitor FAD286 in Two Rodent Models of Hyperaldosteronism: Comparison with the 11 (cid:1) Hydroxylase Inhibitor Metyrapone

F. Fu, Guiqing Liang, M. Beil, 2010 .

Searching for the Lowest Energy Conformation of Substrates in the Carboxypeptidase A Active Site Using Monte Carlo/Energy Minimization Techniques

Guiqing Liang, J. Sebastian, 1998 .

Syntheses and antitumor activities of N'1,N'3-dialkyl-N'1,N'3-di-(alkylcarbonothioyl) malonohydrazide: the discovery of elesclomol.

Lijun Sun, Jim Z Wu, Shoujun Chen, 2013, Bioorganic & Medicinal Chemistry Letters.